Sat.Nov 19, 2022 - Fri.Nov 25, 2022

article thumbnail

A unified, connected foundation is transforming the future of digital trials

Bio Pharma Dive

A holistic approach allows stakeholders to adapt to the ever-increasing number of clinical trials and data points

article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’.

Big Data 285
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI tailors artificial DNA for future drug development

The Pharma Data

AI tailors artificial DNA for future drug development. With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells’ protein production.

DNA 83
article thumbnail

What Matters Most: The Trends That Will Shape Pharma Marketing in 2023

Eversana Intouch

Download the White Paper. Big concepts. Big platforms. Big words. Big decisions. That’s where we all want to play. It’s easy to toss big words around, though: to be provocative, to hype, to make unsupported claims. It’s far more difficult to be precise, accurate, meaningful. To have impact.

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

FDA approves first gene therapy for hemophilia B

Bio Pharma Dive

The treatment, which is for the less common “B” form of the bleeding disorder, will be sold in the U.S. by maker CSL for $3.5 million

article thumbnail

Ozempic compensating for Wegovy’s supply shortage due to high demand

Pharmaceutical Technology

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022.

Sales 229

More Trending

article thumbnail

Medicines for Malaria Venture and Novartis move to phase 3 trial

Pharma Times

Ganaplacide/lumefantrinein new study as world faces emerging resistance to malaria treatments

Medicine 114
article thumbnail

Cancer drugmaker Plexxikon gets new life as Opna Bio

Bio Pharma Dive

Eight months after Daiichi Sankyo shuttered the San Francisco Bay Area subsidiary, Plexxikon’s former CEO is resuscitating its drug research under a new name

Drugs 256
article thumbnail

NICE questions value and efficacy of five Covid-19 drugs with rejection

Pharmaceutical Technology

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies.

Antibody 229
article thumbnail

Teva Finalizes Civil Opioid agreement Terms

The Pharma Data

Teva Finalizes Civil Opioid agreement Terms. TEL AVIV, Israel & PARSIPPANY,N.J.–( –( BUSINESS WIRE)– Teva Pharmaceuticals, aU.S. chapter of Teva Pharmaceutical diligenceLtd.(

82
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

Long-COVID personalized medicine enters Phase 2 trial

BioPharma Reporter

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue. Bio Developments

Medicine 114
article thumbnail

GSK to pull blood cancer drug from US market after study failure

Bio Pharma Dive

The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA

Marketing 253
article thumbnail

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies.

In-Vivo 227
article thumbnail

Quadripartite launches a new platform to attack antimicrobial resistance trouble to mortal and beast health and ecosystems

The Pharma Data

Quadripartite launches a new platform to attack antimicrobial resistance trouble to mortal and beast health and ecosystems.

article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial

BioPharma Reporter

A Phase 3 trial for Northwest Biotherapeuticsâs DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data. Bio Developments

Trials 114
article thumbnail

How brands can tap into wellness – lessons from influencers

Bio Pharma Dive

Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry sectors

Branding 224
article thumbnail

Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment

Pharmaceutical Technology

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults.

Antibody 219
article thumbnail

An arising roadmap to regulating sanitation services

The Pharma Data

An arising roadmap to regulating sanitation services. Kate Medlicott( WHO), Yvonne Magawa( ESAWAS), Peter Mutale( NAWASCO), Chola Mbilima( NWASCO), Sam Drabble( WSUP), Mohammad Said Al Hmaidi( WSRC), Massa Antoine Traore( MoESSD, Mali), Jelena Krsti?(

article thumbnail

Study brings personalised immunotherapy prescriptions closer

Pharma Times

Research showed that prescribing based solely on levels of proteins present is unlikely to be suitable

Protein 112
article thumbnail

Teva taps Sandoz veteran to take over CEO post from Schultz

Bio Pharma Dive

Richard Francis will take over for the retiring Kåre Schultz on Jan. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt

216
216
article thumbnail

FDA grants approval for CSL’s haemophilia B gene therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients.

article thumbnail

Statement on Allergan Nationwide agreement to Resolve Opioid-Affiliated Claims

The Pharma Data

Statement on Allergan Nationwide agreement to Resolve Opioid-Affiliated Claims. Allergan has agreed to a civil agreement moment to resolve opioid-affiliated claims with countries and their separate services and special sections, handed that all conditions are satisfied.

article thumbnail

Depressive therapy Spravato demonstrates superior efficacy

Pharma Times

Research supports use of Spravato nasal spray in adults with major depressive disorder

Research 108
article thumbnail

Merck to buy blood cancer biotech Imago for $1.35B

Bio Pharma Dive

The deal is Merck’s second notable acquisition of a cancer drugmaker in the past year and a half, part of a strategy to diversify its pipeline beyond top-selling immunotherapy Keytruda

216
216
article thumbnail

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

Pharmaceutical Technology

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

article thumbnail

The digital app released to boost physical exertion – and help get children moving

The Pharma Data

The digital app released to boost physical exertion – and help get children moving.

article thumbnail

Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation

Pharma Times

Treatment involves adults with certain forms of advanced stomach and oesophageal cancer

108
108
article thumbnail

The next era of Greater Boston’s biotech boom

Bio Pharma Dive

Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs

207
207
article thumbnail

Japan grants emergency regulatory approval for Shionogi’s Covid-19 drug

Pharmaceutical Technology

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted emergency regulatory approval for Shionogi ’s new anti-SARS-CoV-2 drug, Xocova (ensitrelvir fumaric acid, S-217622), for Covid-19.

article thumbnail

Taking the right forecasting approach for rare diseases

Pharma Phorum

There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH).

article thumbnail

Storm doses first patient with solid tumour drug candidate

Pharma Times

Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development

RNA 108
article thumbnail

Biotech ObsEva sells drug rights to forestall funding crunch

Bio Pharma Dive

In an effort to extend its cash runway and keep its stock listing, ObsEva is offloading rights to an experimental preterm labor drug in a deal with Xoma

Drugs 183
article thumbnail

Merck agrees to acquire Imago for $1.35bn

Pharmaceutical Technology

Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences, through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn.

Sales 207
article thumbnail

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. zbecker. Wed, 11/23/2022 - 10:10